MedTrace Logo

The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus

NCT00620282 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2017-03-08

Study results available
· View outcomes & findings →

Summary

This trial is conducted in the United States of America (USA). The purpose of the trial is to assess the effect of liraglutide on forearm blood flow in subjects with type 2 diabetes who are on diet and lifestyle changes or treated with metformin alone.

Conditions

Interventions

DRUG

liraglutide

Stepwise dose increase, s.c. (under the skin) injection, once daily

DRUG

placebo

Liraglutide placebo, stepwise dose increase, s.c. (under the skin) injection, once daily

DRUG

glimepiride

Tablets, 1 - 4 mg daily

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00620282 on ClinicalTrials.gov